205 related articles for article (PubMed ID: 38281279)
1. PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition.
Huang C; Zhang X; Wang S; Shen A; Xu T; Hou Y; Gao S; Xie Y; Zeng Y; Chen J; Lin R; Zhang Y; Wan C; Cai Y
Apoptosis; 2024 Jun; 29(5-6):816-834. PubMed ID: 38281279
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase-2 depletion reduces doxorubicin-induced damage through SIRT1 induction.
Szántó M; Rutkai I; Hegedus C; Czikora Á; Rózsahegyi M; Kiss B; Virág L; Gergely P; Tóth A; Bai P
Cardiovasc Res; 2011 Dec; 92(3):430-8. PubMed ID: 21921080
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z
J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442
[TBL] [Abstract][Full Text] [Related]
4. Protection against Doxorubicin-Related Cardiotoxicity by Jaceosidin Involves the Sirt1 Signaling Pathway.
Liu Y; Zhou L; Du B; Liu Y; Xing J; Guo S; Li L; Chen H
Oxid Med Cell Longev; 2021; 2021():9984330. PubMed ID: 34422218
[TBL] [Abstract][Full Text] [Related]
5. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction.
Zhuang X; Sun X; Zhou H; Zhang S; Zhong X; Xu X; Guo Y; Xiong Z; Liu M; Lin Y; Zhang M; Liao X
Mech Ageing Dev; 2021 Apr; 195():111442. PubMed ID: 33539906
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-22 inhibition prevents doxorubicin-induced cardiotoxicity via upregulating SIRT1.
Xu C; Liu CH; Zhang DL
Biochem Biophys Res Commun; 2020 Jan; 521(2):485-491. PubMed ID: 31677784
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.
Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J
Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055
[TBL] [Abstract][Full Text] [Related]
8. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.
Liu D; Ma Z; Di S; Yang Y; Yang J; Xu L; Reiter RJ; Qiao S; Yuan J
Free Radic Biol Med; 2018 Dec; 129():59-72. PubMed ID: 30172748
[TBL] [Abstract][Full Text] [Related]
9. Dosing depending on SIRT3 activity attenuates doxorubicin-induced cardiotoxicity via elevated tolerance against mitochondrial dysfunction and oxidative stress.
Yang N; Ma H; Jiang Z; Niu L; Zhang X; Liu Y; Wang Y; Cheng S; Deng Y; Qi H; Wang Z
Biochem Biophys Res Commun; 2019 Sep; 517(1):111-117. PubMed ID: 31303273
[TBL] [Abstract][Full Text] [Related]
10. Evidences for the mechanism of Shenmai injection antagonizing doxorubicin-induced cardiotoxicity.
Wu YP; Zhang S; Xin YF; Gu LQ; Xu XZ; Zhang CD; You ZQ
Phytomedicine; 2021 Jul; 88():153597. PubMed ID: 34111614
[TBL] [Abstract][Full Text] [Related]
11. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
[TBL] [Abstract][Full Text] [Related]
12. Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte.
Kumar SN; Konorev EA; Aggarwal D; Kalyanaraman B
J Proteomics; 2011 May; 74(5):683-97. PubMed ID: 21338723
[TBL] [Abstract][Full Text] [Related]
13. Time course of cardiomyopathy induced by doxorubicin in rats.
Medeiros-Lima DJM; Carvalho JJ; Tibirica E; Borges JP; Matsuura C
Pharmacol Rep; 2019 Aug; 71(4):583-590. PubMed ID: 31174019
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
[TBL] [Abstract][Full Text] [Related]
15. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Pacher P; Liaudet L; Bai P; Virag L; Mabley JG; Haskó G; Szabó C
J Pharmacol Exp Ther; 2002 Mar; 300(3):862-7. PubMed ID: 11861791
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress.
Lin J; Fang L; Li H; Li Z; Lyu L; Wang H; Xiao J
Eur J Pharmacol; 2019 Sep; 859():172490. PubMed ID: 31229536
[TBL] [Abstract][Full Text] [Related]
17. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1.
Sun Z; Lu W; Lin N; Lin H; Zhang J; Ni T; Meng L; Zhang C; Guo H
Biochem Pharmacol; 2020 May; 175():113888. PubMed ID: 32112883
[TBL] [Abstract][Full Text] [Related]
18. Cardiac SIRT1 ameliorates doxorubicin-induced cardiotoxicity by targeting sestrin 2.
Wang A J; Tang Y; Zhang J; Wang B J; Xiao M; Lu G; Li J; Liu Q; Guo Y; Gu J
Redox Biol; 2022 Jun; 52():102310. PubMed ID: 35452917
[TBL] [Abstract][Full Text] [Related]
19. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
McLaughlin D; Zhao Y; O'Neill KM; Edgar KS; Dunne PD; Kearney AM; Grieve DJ; McDermott BJ
Br J Pharmacol; 2017 Nov; 174(21):3677-3695. PubMed ID: 28261787
[TBL] [Abstract][Full Text] [Related]
20. SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function.
Wang P; Wang L; Lu J; Hu Y; Wang Q; Li Z; Cai S; Liang L; Guo K; Xie J; Wang J; Lan R; Shen J; Liu P
J Mol Cell Cardiol; 2019 Aug; 133():125-137. PubMed ID: 31199952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
